RNA Avidity Biosciences, Inc.: institutional ownership and insider trading
15 funds reported holding $1.09B of Avidity Biosciences, Inc. in their latest 13F filings; in Q2 2026 funds net bought $0, with 0 new positions and 1 funds selling out; over the last 12 months insiders bought $0 and sold $4.23M on the open market; over its last four quarters it reported revenue of $18.8M and net income of −$685M.
RNA revenue and earnings
- Quarter ended Dec 31, 2025: revenue $860K, net income −$237M, EPS -1.59
- Quarter ended Sep 30, 2025: revenue $12.5M, net income −$174M, EPS -1.27
- Quarter ended Jun 30, 2025: revenue $3.85M, net income −$157M, EPS -1.21
- Quarter ended Mar 31, 2025: revenue $1.57M, net income −$116M, EPS -0.90
Largest institutional holders of RNA
- VANGUARD GROUP INC — $985M
- KRYGER CAPITAL Ltd — $75.4M
- Nuveen Asset Management, LLC — $10.3M
- EFG Asset Management (North America) Corp. — $6.50M
- AXA Investment Managers S.A. — $4.43M
- ANGELO GORDON & CO., L.P. — $3.25M
- WOLVERINE TRADING, LLC — $1.76M
- CIBC WORLD MARKETS CORP — $552K
- Eisler Capital Management Ltd. — $322K
- Orion Portfolio Solutions, LLC — $311K
Recent RNA insider trades
- Jan 21, 2026: McCarthy Teresa sold 2,929 shares ($212K)
- Jan 21, 2026: Levin Arthur A sold 1,758 shares ($127K)
- Jan 21, 2026: MacLean Michael F sold 4,542 shares ($329K)
- Jan 21, 2026: Flanagan W. Michael sold 6,534 shares ($473K)
5%+ owners
- The Vanguard Group: 9.6% (Schedule 13G/A, filed Oct 30, 2025)
- BlackRock, Inc.: 6.4% (Schedule 13G/A, filed Oct 17, 2025)
- Avoro Capital Advisors LLC: 5.5% (Schedule 13G/A, filed Feb 17, 2026)
Who owns the most RNA stock?
The largest institutional holders of Avidity Biosciences, Inc. in the latest 13F filings are VANGUARD GROUP INC ($985M), KRYGER CAPITAL Ltd ($75.4M), Nuveen Asset Management, LLC ($10.3M).
Are insiders buying or selling RNA?
Over the last 12 months insiders bought $0 and sold $4.23M of Avidity Biosciences, Inc. stock on the open market (SEC Form 4).
What was RNA's revenue last quarter?
Avidity Biosciences, Inc. reported revenue of $860K for the quarter ended December 31, 2025, with net income of −$237M.